Karen S. Wright
Comptroller/Controller/Auditor at STRUCTURE THERAPEUTICS INC.
Karen S. Wright active positions
| Companies | Position | Start | End |
|---|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Comptroller/Controller/Auditor | - | - |
Career history of Karen S. Wright
Former positions of Karen S. Wright
| Companies | Position | Start | End |
|---|---|---|---|
| JAGUAR HEALTH, INC. | Comptroller/Controller/Auditor | 2015-12-14 | 2019-08-08 |
| Director of Finance/CFO | 2015-12-14 | 2019-08-08 | |
| Treasurer | 2015-12-14 | 2019-08-08 | |
Clene Nanomedicine, Inc.
 Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Director of Finance/CFO | 2014-07-31 | 2015-10-31 |
| VERACYTE, INC. | Comptroller/Controller/Auditor | 2011-05-31 | 2014-04-30 |
| VIA PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 2007-06-06 | - |
| Director of Finance/CFO | 2010-05-06 | 2011-02-28 | |
VIA Pharmaceuticals, Inc. /Old/
 VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 2006-11-30 | 2010-12-31 |
| INTERMUNE INC | Comptroller/Controller/Auditor | 2004-11-30 | 2006-11-30 |
| CYTOKINETICS, INCORPORATED | Director of Finance/CFO | 2001-10-31 | 2004-11-30 |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Director of Finance/CFO | 1996-12-31 | 2000-12-31 |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of Karen S. Wright
| Haas School of Business | Undergraduate Degree |
Statistics
International
| United States | 13 |
Operational
| Comptroller/Controller/Auditor | 6 |
| Director of Finance/CFO | 6 |
| Treasurer | 2 |
Sectoral
| Health Technology | 11 |
| Consumer Services | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 5 |
|---|---|
| VIA PHARMACEUTICALS, INC. | Health Technology |
| CYTOKINETICS, INCORPORATED | Health Technology |
| VERACYTE, INC. | Health Technology |
| JAGUAR HEALTH, INC. | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Private companies | 6 |
|---|---|
VIA Pharmaceuticals, Inc. /Old/
VIA Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology VIA Pharmaceuticals, Inc. develops pharmaceutical products. It focuses on small-molecule drugs that target inflammation in the blood vessel wall as an innovative approach to treatment of cardiovascular disease. The company's strategy is to identify, acquire and develop compounds that intervene in the process of vascular inflammation, to reduce the incidence of major cardiovascular events and provide a significant clinical benefit to patients. It was founded in June, 2004 by Thomas Quertermous, Adeoye Y. Olukotun and Douglass B. Given. VIA is headquartered in San Francisco, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Elan Pharmaceuticals, LLC
Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Health Technology |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Jaguar Animal Health, Inc.
 Jaguar Animal Health, Inc. Pharmaceuticals: MajorHealth Technology Jaguar Animal Health, Inc. engages in the development and commercialization of gastrointestinal products for companion and production animals. Its product, Canalevia, is the company's prescription drug product candidate for the treatment of various forms diarrhea in dogs. It also developed its non-prescription product, Neonorm Calf, which helps dairies and beef farms proactively retain fluid in calves. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA. | Health Technology |
Clene Nanomedicine, Inc.
Clene Nanomedicine, Inc. Pharmaceuticals: MajorHealth Technology Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company, which develops therapeutic candidates for neurodegenerative diseases. It focuses on the development of therapeutic nanocatalyst, CNM-Au8, for treatment of neurodegenerative diseases with a Phase 3 study underway in amyotrophic lateral sclerosis (ALS), and concurrent Phase 2 clinical programs ongoing for the neuroreparative treatment of multiple sclerosis, Parkinson's disease, and ALS. The company was founded by Reed N. Wilcox and Mark G. Mortenson in 2013 and and is headquartered in Salt Lake City, UT. | Health Technology |
- Stock Market
- Insiders
- Karen S. Wright
- Experience
